AGC Biologics has more than 20 years of experience delivering a wide range of microbial programs to biopharma customers. The German site is its center of excellence for pDNA production and part of the company’s end-to-end cell and gene therapy offering.

The CDMO’s network spans the US, Europe and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder, Colorado; Copenhagen, Denmark; Milan, Italy; and Chiba, Japan in addition to Heidelberg. In March, the company announced expansion plans for Milan.

AGC Biologics, headquartered in Seattly, has been formed by integration of Asahi Glass Company (AGC) Bioscience, CMC Biologics, Biomeva and Molecular Medicine. Currently employing more than 1,700 people worldwide, AGC Biologics specializes in development and manufacture of mammalian and microbial-based therapeutic proteins, viral vectors and genetically engineered cells in addition to pDNA.

Author: Dede Williams, Freelance Journalist